Contribute Try STAT+ Today

In the latest look at conflicts of interest in science, a new analysis found 15% of the authors of editorials accompanying studies in prestigious medical journals about heart drugs and devices had financial ties to the companies that sponsored the clinical trials, but they did not disclose the relationships.

Generally, financial ties between study authors and manufacturers have generated considerable interest due to concerns over influencing medical research and practice. But this latest analysis, which was published in JAMA Internal Medicine, extends this unease to editorial writers, who are also in a position to sway thinking about trial results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment